April 15, 2013 — Tomosynthesis (3-D mammography) is better able to show infiltrating ductal carcinoma than 2-D mammography in women at increased risk of breast cancer, a new clinical study shows.

As part of the study, six breast imaging specialists reviewed both 2-D and 3-D mammography images of 56 cancers diagnosed in patients at intermediate or high risk of breast cancer.

"We found that 41 percent (23/56 cancers) were better seen on tomosynthesis and 4 percent (2/56) were only seen on tomosynthesis," said Sarah O'Connell, a lead author of the study. Thirty percent of cancers (17/56) were better seen on 2-D mammography but none were only seen on 2-D mammography. The remaining were rated by the breast imaging specialists as being equally visible on both 2-D and 3- imaging, she said.

"The majority of cancers seen better or only on tomosynthesis were predominantly infiltrating ductal carcinoma, which typically presents as a mass, focal asymmetry or architectural distortion," said O'Connell.

The majority of cancers seen better or only on 2-D mammography were ductal carcinoma in situ (DCIS) which presents as calcifications, she said. "This was not surprising because tomosynthesis gives us the ability to scroll through the breast tissue in 1 mm sections, which provides us with more detail, but also may separate a cluster of calcifications, making them more difficult to identify," said O'Connell. O'Connell noted that work is being done to optimize visualization of calcifications on tomosynthesis.

The benefits of tomosynthesis are especially relevant to women at increased risk of breast cancer who have increased anxiety about breast screening and have the potential for biologically aggressive cancers, said O'Connell.

The study is part of the electronic exhibit program at the ARRS Annual Meeting in Washington, D.C.


Related Content

News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
News | Mammography

April 24, 2025 — GE HealthCare will feature its latest advancements in diagnostic accuracy and patient-centered breast ...

Time April 24, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
News | Artificial Intelligence

Feb. 19, 2025 — SimonMed Imaging and HeartLung Technologies have signed a strategic partnership to offer HeartLung's AI ...

Time March 04, 2025
arrow
News | Ultrasound Imaging

Jan. 28, 2025 — GE HealthCare recently announced it has received 510(k) clearance from the United States Food and Drug ...

Time January 29, 2025
arrow
News | Breast Imaging

Jan. 8, 2025 — ScreenPoint Medical has acquiredf Biomediq A/S, a research-based company focused on the research ...

Time January 10, 2025
arrow
News | Breast Imaging

Dec.11, 2024 — iCAD, Inc., a provider of clinically proven AI-powered cancer detection solutions, recently announced ...

Time December 18, 2024
arrow
News | Mammography

Dec. 5, 2024 — At RSNA 2024, Lunit and Volpara Health announced their unified vision, focusing on a comprehensive ...

Time December 05, 2024
arrow
News | Mammography

Nov. 26, 2024 — GE HealthCare has introduced the Pristina Via* mammography system designed to enhance the screening ...

Time December 02, 2024
arrow
News | Artificial Intelligence

Dec. 2, 2024 — Lunit recently unveiled follow-up findings from the ScreenTrustCAD trial. This study, conducted at Capio ...

Time December 02, 2024
arrow
Subscribe Now